LOS ANGELES--(BUSINESS WIRE)--
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. (“Cellectis” or the “Company”) (Nasdaq: CLLS).
If you purchased or otherwise acquired Cellectis shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at [email protected].
The investigation focuses on whether Cellectis and certain of its officers and/or directors violated federal securities laws. On September 5, 2017, the Company announced that the U.S. Food & Drug Administration suspended two early-stage studies for the Company’s experimental blood cancer treatment UCART123, following the death of a patient. Following this news, Cellectis’ stock price dropped.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected].
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005765/en/
